Brian Leyland - Jones, M.D., Ph.D.

Brian Leyland - Jones, M.D., Ph.D.
Cancer Therapies

Emory University

Research Interest

1. Translational research (Genomics & Proteomics):

Molecular profiling of formalin-fixed, paraffin-embedded (FFPE) tumor samples from several clinical trials using a commercial 502-gene cancer panel in the DASL assay in order to investigate differential gene expression patterns and identify genes or gene sets that correlate with clinical outcome.
Validation of a 512-gene custom breast cancer panel in the DASL assay molecular profiling platform using FFPE tumor samples.
Confirming and extending the Oncotype DX results using the DASL assay in conjunction with our custom breast cancer 512-gene panel.
Identification of serum proteomic signatures from patients enrolled in several clinical trials using MALDI-TOF and iTRAQ prteomic platforms

2. Preclinical and biomarkers:

Assess the efficacy of novel cancer agents in different pre-clinical tumor models.
Examine the effects of the concomitant combination of novel or existing cancer agents with other chemo and/or targeted therapies.
Identify surrogate markers of response for different animal tumor samples.
Correlate differential expression profiles with treatment outcome
Identify the best treatment regimens to help design future clinical trials.

Research Vision

To develop a state-of-the-art Cancer Institute that will bring together clinical, translational and basic research for the purpose of optimizing the treatment modalities and improving the quality of life of all cancer patients.
To identify prognostic and predictive biomarkers for the individualization of therapeutic strategies for cancer patients.

In the Lab

Our own 512-gene custom breast cancer panel
The Illumina DASL molecular profiling platform

Why Georgia?

Emory University brings a tremendous array of resources to the fight against cancer. We are well positioned here to harness the resources of Emory University as well as our partners in research and education at the American Cancer Society, the CDC, the Georgia Cancer Coalition and the Georgia Research Alliance. In addition, our work with Georgia Tech and our research ties to the University of Georgia will only continue to grow in depth and breadth. Through collaboration with the exceptional resources we have here in Georgia, we can make significant strides in development of prevention and personalized treatment for all types of cancer.

Other Emory University Eminent Scholars